ReviewDeutsches Arzteblatt international2026
Cardiac Amyloidosis: Pathogenesis, Diagnosis, and Treatment.
Review in Deutsches Arzteblatt international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe administrative prevalence of cardiac amyloidosis is approximately 50 per 100 000 person-years. The pathophysiology of amyloidosis involves a misfolding of proteins with a beta-pleated sheet structure. This leads to the deposition of insoluble fibrils in the interstitium, which, in turn, impair organ function and cause a variety of diseases. Systemic types are the most common, especially light-chain (AL) and transthyretin (ATTR) amyloidosis with cardiac involvement. In this article, we present the diagnostic evaluation of amyloidosis and recent developments in its treatment.
methodsThis review is based on publications retrieved by a selective search in PubMed for registry studies, meta-analyses, randomized controlled trials, systematic reviews, guidelines, and current position papers on "cardiac amyloidosis," "ATTR amyloidosis," "cardiac amyloidosis epidemiology," "cardiac amyloidosis treatment," and "ATTR amyloidosis treatment."
resultsCardiac amyloidosis markedly impairs cardiac function and carries a poor prognosis as well as elevated mortality. The diagnosis is mainly based on specialized imaging studies including echocardiography, cardiac magnetic resonance imaging, and scintigraphy. The goal of treatment is to slow amyloid deposition. In ATTR amyloidosis, transthyretin stabilizers or RNA silencers can stabilize the clinical course: the use of tafamidis has been found to be associated with better outcomes and lower overall mortality at 30 months compared with placebo (HR 0.70 [0.51; 0.96]). Vutrisiran also lowers overall mortality and reduces recurrent cardiovascular events compared to placebo (HR 0.72 [0.56; 0.93]). Cardiac complications and comorbidities can be treated, depending on left ventricular function and drug tolerability, with SGLT2 inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, among other drugs.
conclusionAdvanced cardiac amyloidosis carries a poor prognosis; early diagnosis and targeted treatment are of decisive importance. Better outcomes are now possible with the aid of improved imaging methods, disease-modifying treatment options, and the treatment of cardiac complications. Further approaches are now being studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.